fenretinide and Colitis--Ulcerative

fenretinide has been researched along with Colitis--Ulcerative* in 1 studies

Other Studies

1 other study(ies) available for fenretinide and Colitis--Ulcerative

ArticleYear
Fenretinide regulates macrophage polarization to protect against experimental colitis induced by dextran sulfate sodium.
    Bioengineered, 2021, Volume: 12, Issue:1

    Fenretinide (4-HPR), a synthetic retinoid, has attracted attention for its anti-inflammation activity. However, few studies have evaluated the effects of 4-HPR on ulcerative colitis (UC). The present study was performed to investigate the therapeutic effects of 4-HPR on UC, and to explore the mechanisms mainly focused on macrophage polarization involved in this progress. Intraperitoneally administered 4-HPR particularly at dose of 100 mg/kg obviously alleviated UC symptoms and restrained the mRNA expression of colonic IL-1β, IL-6, and TNF-α in dextran sulfate sodium (DSS)-induced mice. Further analysis showed that 4-HPR decreased the mRNA expression of M1 macrophage markers IL-12 and iNOS, while increased M2 macrophage markers Ym1, Arg1 and MRC1 in colonic tissue of mice received DSS. Consistently, an

    Topics: Animals; Cell Polarity; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Fenretinide; Macrophages; Male; Mice; Mice, Inbred C57BL; Protective Agents; RAW 264.7 Cells

2021